Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fate Therapeutics commences Phase 2 ProHema study
The controlled study will enroll around 45 suitable adult patients and randomize them into 2:1 ratio with either ProHema together with an unmanipulated cord blood unit or two
The controlled study will enroll around 45 suitable adult patients and randomize them into 2:1 ratio with either ProHema together with an unmanipulated cord blood unit or two
Based on the Hydros-TA technology, Jingfeng plans to commercialize an intra-articular therapy, designed for treating the pain associated with osteoarthritis of the knee, in China. In exchange for
The bovine anti-tumor necrosis factor polyclonal antibody is based on Avaxia’s oral antibody platform and is thus directly delivered to the GI tract where the inflammation occurs. Company
Fusilev, a folate analog, is indicated for use in combination chemotherapy with 5-fluorouracil for analgesic treatment of colorectal cancer in 2011. With the approval of the new facility,
The LifeMap Discovery platform provides data-mining capabilities and bioinformatics applications as well as integrates embryonic development and stem cell biology with molecular, cellular, anatomical, and disease-related information. In
The patent issued by the United States Patent and Trademark Office (USPTO) under the name of "Methods for Stabilizing Retinoids, Retinoid Containing Composition, and Methods of Using a
EMH Healthcare has selected Amcom to improve the workflow for both radiologists and ER physicians, which leads to good patient care. EMH Healthcare imaging services department manager Michelle
IL-17E is a pro-inflammatory cytokine protein with a potential to stimulate immune response against cancer cells. Cancer Research UK’s Drug Development Office (DDO) will fund and carry out
As part of the alliance, the companies will employ their respective technologies to constitute diverse lantipeptide-based libraries. Under the alliance, MorphoSys will also license the LanthioPep technology for
Pursuant to the deal, Minapharm will leverage VTU´s Pichia pastoris protein expression technology in rHSA production and VTU will contribute expression strain development and bioprocess optimization process for